How obesity coverage frames are diverging between cardiovascular-prevention and obesity-only indications

Why the coverage frames are diverging

The GLP-1 receptor agonist class has multiple approved indications across the major members:

• Type 2 diabetes (long-established)
• Obesity (semaglutide, liraglutide, tirzepatide depending on dose and formulation)
• Cardiovascular outcomes prevention in established cardiovascular disease (semaglutide, liraglutide CV outcomes data)
• MASH (semaglutide approval expanding)
• Adjacent expansion indications (HFpEF, sleep apnea, kidney disease)

The cardiovascular-prevention frame and the obesity-only frame are emerging as commercially distinct because:

• Cardiovascular prevention has established payer logic from the statin era. Coverage is generally accessible for patients meeting cardiovascular-risk thresholds, with prior-authorisation criteria that engage with cardiovascular risk factors rather than weight
• Obesity-only coverage faces structural payer hesitation rooted in historical framing of obesity as a lifestyle condition rather than a metabolic disease. Coverage is more variable, with prior-authorisation criteria that often require BMI thresholds, documented weight-management attempts, or comorbidity profiles
• The eligible-population definitions differ. Cardiovascular-prevention eligible population is defined by cardiovascular risk profile; obesity-only eligible population is defined by weight and weight-related comorbidity

The result is that the same molecule can have substantially different coverage outcomes depending on the indication framing in which it is prescribed.

How the bifurcation looks across markets

United States: Cardiovascular-prevention indications generally see broader commercial coverage. Obesity-only coverage is variable, with substantial Medicare coverage gaps and uneven commercial-payer policy.

United Kingdom: NICE has engaged with obesity therapy through specific eligible-population definitions tied to BMI and comorbidity criteria. The cardiovascular-prevention frame has seen separate engagement.

Germany and France: AMNOG and HAS frameworks have distinct positions on obesity-only and cardiovascular-prevention frames, with reimbursement decisions reflecting the indication-specific evidence packages.

Other markets: Variable, with the obesity-only versus cardiovascular-prevention bifurcation playing out differently depending on each market's pharmaceutical-budget structure.

What this means for commercial planning

For sponsors of GLP-1 assets, obesity-relevant pipeline, and adjacent metabolic-disease programs:

• The indication-framing decision is a strategic commercial decision. Programs positioned to the cardiovascular-prevention frame access different payer logic than programs positioned to the obesity-only frame
• Real-world data generation needs to support the indication framing the asset is positioned to. Cardiovascular-event reduction data supports one framing; weight-loss-and-comorbidity data supports another
• Adjacent indications (MASH, sleep apnea, HFpEF) are inheriting the bifurcation. Indications that frame as cardiovascular or organ-specific access different payer logic than indications that frame as obesity-related

What we are watching

• Coverage policy evolution across markets and the rate of bifurcation between the two indication frames
• Real-world utilisation data showing the coverage-driven differences in prescribing patterns
• Adjacent indication launches (HFpEF expansion, sleep apnea, MASH) and how they engage with the bifurcation